Effect of two-level nerve block in knee replacement surgery
Two-level Vs One-level Erector Spinae Plane Block in Total Knee Arthroplasty
This study tests if a special nerve block can help older patients have less pain and need fewer painkillers after knee replacement surgery.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 65 Years to 100 Years |
| Sex | All |
| Sponsor | Poznan University of Medical Sciences Academic / other |
| Locations | 1 site (Poznan, Poznań) |
| Trial ID | NCT06470542 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of a two-level erector spinae plane block (ESPB) on patients undergoing total knee arthroplasty. The approach aims to reduce postoperative pain and minimize the need for opioids by administering Ropivacaine, a local anesthetic, at two different levels. The trial will include patients aged 65 to 100 who are scheduled for knee replacement surgery and can provide informed consent. By evaluating pain levels and opioid consumption post-surgery, the study seeks to enhance recovery outcomes for elderly patients.
Who should consider this trial
Good fit: Ideal candidates are patients aged 65 to 100 scheduled for total knee arthroplasty who can provide informed consent.
Not a fit: Patients with cognitive impairments or language barriers that prevent them from providing informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce postoperative pain and opioid use in elderly patients undergoing knee replacement surgery.
How similar studies have performed: Other studies have shown promising results with regional anesthesia techniques in reducing postoperative pain, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients scheduled for total hip arthroplasty * patients aged \>65 and \<100 years * patients able to provide informed consent * patients able to reliably report symptoms to the research team Exclusion Criteria: * inability to provide first-party consent due to cognitive impairment or a language barrier
Where this trial is running
Poznan, Poznań
- Poznan University of Medical Sciences — Poznan, Poznań, Poland (Recruiting)
Study contacts
- Study coordinator: Malgorzata Domagalska, M.D. Ph.D.
- Email: mdomagalska@ump.edu.pl
- Phone: (61) 873-83-03
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.